Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

198 Applying Pharmacogenomics in Therapeutics
40. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. (1990). An
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting
for half the variance of serum enzyme levels. Journal of Clinical Investigation, 86:
1343–1346.
41. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. (1992).
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin
I-converting enzyme (ACE) gene controls plasma ACE levels. American Journal
of Human Genetics, 51: 197–205.
42. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A,
Kingma JH, Witteman JC, Stricker BH. (2005). Mortality in patients with hypertension
on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the
ACE insertion/deletion polymorphism. Pharmacogenetics & Genomics, 15: 75–81.
43. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. (2002).
Pharmacogenetic approaches to hypertension therapy: Design and rationale for the
Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics
Journal, 2: 309–317.
44. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, Chapman N, et al.
(2003). The ACE gene I/D polymorphism is not associated with the blood pressure and
cardiovascular benefits of ACE inhibition. Hypertension, 42: 297–303.
45. Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML,
Jukema JW. (2011). A systematic review on pharmacogenetics in cardiovascular
d isease: Is it ready for clinical application? European Heart Journal, 33: 165–175.
46. Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, Bertrand M,
et al. (2010). Genetic determinants of treatment benefit of the angiotensin-converting
enzyme-inhibitor perindopril in patients with stable coronary artery disease. European
Heart Journal, 31: 1854–1864.
47. Redon J, Luque-Otero M, Martell N, Chaves F. (2004). Renin–angiotensin system
gene polymorphisms: Relationship with blood pressure and microalbuminuria in
telmisartan-treated hypertensive patients. The Pharmacogenomics Journal, 5: 14–20.
48. Ortlepp J, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. (2002). Variants
of the CYP11B2 gene predict response to therapy with candesartan. European Journal
of Pharmacology, 445: 151–152.
49. Huang CC, Chung CM, Hung SI, Leu HB, Wu TC, Huang PH, Lin SJ, Pan WH, Chen JW.
(2011). Genetic variation in renin predicts the effects of thiazide diuretics. European
Journal of Clinical Investigation, 41(8): 828–835. doi:10.1111/j.1365-2362.2011.02472.x.
50. Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E,
et al. (2010). Effect of ACE insertion/deletion and 12 other polymorphisms on clinical
outcomes and response to treatment in the LIFE study. Pharmacogenetics and Genomics,
20(2): 77–85. doi: 10.1097/FPC.0b013e328333f70b.
51. Beeks E. (2004). Adducin Gly460Trp polymorphism and renal hemodynamics in
essential hypertension. Hypertension, 44: 419–423.
52. Lynch A, Boerwinkle E, Davis B, Ford C, Eckfeldt J, Leiendecker-Foster C, Arnett D.
(2008). Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular
disease outcomes in patients with hypertension. JAMA, 299: 296–307.
53. Katz A. (1986). Pharmacology and mechanisms of action of calcium-channel blockers.
Journal of Clinical Hypertension, 2: 28S–37S.
54. Bremer T, Man A, Kask K, Diamond C. (2006). CACNA1C polymorphisms are associated
with the efficacy of calcium channel blockers in the treatment of hypertension.
Pharmacogenomics, 7: 271–279.
55. Langaee T, Gong Y, Yarandi H, Katz D, Cooper-Dehoff R, Pepine C, Johnson J. (2007).
Association of CYP3A5 polymorphisms with hypertension and antihypertensive
response to verapamil. Clinical Pharmacology & Therapeutics, 81: 386–391.